Clinical Trial Update: Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating intravenous GC4419 for reducing incidence and severity of esophagitis in lung cancer patients undergoing chemoradiotherapy; study termi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophagitis
• Lung Cancer

Drugs mentioned

• GC4419

Snippet

Sponsor: Galera Therapeutics, Inc. | Conditions: Esophagitis | Phase 2 | Status: TERMINATED | Results posted: 2023-03-23